Notably, the effect was greatest when T cells from NPM1mut patients were stimulated with the NPM1mut peptide, suggesting that anti-PD-1 antibodies, such as nivolumab, could be used to treat AML NPM1mut. This evidence concerns the gene PDCD1 and acute myeloid leukemia.